TransMedics
Clinical trials sponsored by TransMedics, explained in plain language.
A medical technology company developing organ transplant preservation systems.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Heart transplant breakthrough? OCS device Follow-Up study tracks 5-Year survival Results expected Oct 2026 (estimated)
- New device aims to boost heart transplant success Results expected Jan 2027 (estimated)
-
Beating heart machine for transplants under Real-World watch
Disease control OngoingThis registry follows 350 adult heart transplant patients whose donor hearts were kept alive and beating using the OCS Heart System before transplant. The goal is to see how well patients do one year after surgery. The device may allow more donor hearts to be used, especially tho…
Sponsor: TransMedics • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Heart transplant breakthrough? OCS device Follow-Up study tracks 5-Year survival
Disease control OngoingThis study follows 276 heart transplant patients who received a donor heart preserved with the OCS Heart device. Researchers will track survival and other outcomes for up to 5 years after transplant. The goal is to confirm the long-term safety and effectiveness of using OCS-prese…
Sponsor: TransMedics • Aim: Disease control
Last updated Jun 26, 2026 14:54 UTC